RE: Damage12 Jan 2023 07:58
Well on the point about sales, we know they appointed a sales manager (expensive) before the first FDA approval attempt failed yet we do not know now what the marketing strategy is now? It is all well and good having a product, it is how you market it that is the key, and, to my mind at least Richard needs to communicate to the investors as a matter of urgency. Every time he has been quiet the SP has drifted lower and lower which is not in the company's best interest if, they are looking for future capital injection at any point.
I am not into this trust the board mantra that people go on about, we are eighteen months behind and we need to know what the plan is now for fast sales given the balance sheet restrictions. that's is my view anyhow.